Table 1. Patients’ characteristics.

Patients	Overall, 311 [%]	SII ≥1,270, 179 [58]	SII <1,270, 132 [42]	P value
Gender				0.9645
Male	216 [69]	124 [69]	92 [70]
Female	95 [31]	55 [31]	40 [30]
Age, years [range]	68 [25−86]	65 [25−83]	68 [29−86]	0.0232
ECOG				0.8473
ECOG-PS ≥2	21 [7]	13 [7]	8 [6]
ECOG-PS <2	290 [93]	166 [93]	124 [94]
Histology				0.0004
Adenocarcinoma	189 [61]	121 [68]	68 [51]
Squamous carcinoma	69 [22]	31 [17]	38 [29]
Other	53 [17]	27 [15]	26 [20]
NOS (not otherwise specified)	50 [16]	25 [14]	25 [19]
Mixed-histology	3 [1]	2 [1]	1 [1]
Tumor stage				0.0154
Stage III	75 [24]	36 [20]	39 [30]
Stage IV	236 [76]	143 [80]	93 [70]
EGFR mutation status				0.0575
Wild-type	278 [89]	164 [92]	114 [86]
Mutated	33 [11]	15 [8]	18 [14]
Smoking history				0.7665
Former/current smokers	236 [76]	138 [77]	98 [74]
Never smokers	75 [24]	41 [23]	34 [26]
Common sites of metastasis
Lung	136 [44]	83 [46]	53 [40]
Bone	80 [26]	56 [31]	24 [18]
Nervous system	37 [12]	22 [12]	15 [11]
Liver	45 [14]	29 [16]	16 [12]
First-line therapy
Platinum-based chemotherapy	240 [77]	148 [83]	92 [70]
Non platinum-based	50 [16]	18 [10]	32 [24]
EGFR-TKI	21 [7]	13 [7]	8 [6]
Response to first-line therapy
Partial response	109 [35]	64 [36]	45 [34]
Stable disease	73 [24]	33 [18]	40 [30]
Progression disease	129 [41]	82 [46]	47 [36]